SCHEMBL23914586

SCHEMBL23914586

CCOC(=O)C(C)n1nc(C)c2ccc(OC)cc2c1=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
KDM4E B2RXH2 5/20 0.50
ALDH1A1 P00352 4/20 0.50
KMT2A Q03164 3/20 0.50
LMNA P02545 2/20 0.50
MEN1 O00255 2/20 0.50
HSD17B10 Q99714 2/20 0.50
TSHR P16473 1/20 0.50
MAPK1 P28482 1/20 0.50
ATM Q13315 1/20 0.44
PRNP P04156 1/20 0.43
NPSR1 Q6W5P4 1/20 0.42
PDE4D Q08499 1/20 0.41
ELANE P08246 1/20 0.41
HPGD P15428 2/20 0.40
KAT2B Q92831 1/20 0.40
GLA P06280 1/20 0.40
GAA P10253 1/20 0.40
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23914616 0.86 MAPT (0.48) MAPTL3MBTL1KDM4EALDH1A1KMT2A
SCHEMBL23909111 0.82 MAPT (0.73) MAPTL3MBTL1KDM4EALDH1A1KMT2A
SCHEMBL23915561 0.80 MAPT (0.56) MAPTL3MBTL1KDM4EALDH1A1KMT2A
SCHEMBL27435500 0.70 NPBWR1 (0.47) KDM4EALDH1A1KMT2ALMNAMEN1
SCHEMBL29451655 0.70 KDM4E (0.50) MAPTL3MBTL1KDM4EALDH1A1KMT2A
SCHEMBL23914872 0.70 MAPT (0.53) MAPTL3MBTL1KDM4EALDH1A1KMT2A
SCHEMBL21273677 0.69 KDM4E (0.58) MAPTL3MBTL1KDM4EALDH1A1KMT2A
SCHEMBL21245454 0.69 ALDH1A1 (0.55) MAPTL3MBTL1KDM4EALDH1A1KMT2A
SCHEMBL24076914 0.69 GAA (0.50) MAPTL3MBTL1KDM4EALDH1A1KMT2A
SCHEMBL23908905 0.68 MAPT (0.67) MAPTL3MBTL1KDM4EALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3649119-B1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS GALAPAGOS NV (BE) 2021-11-03 EP disclosed
US-20210315893-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS GILEAD SCIENCES, INC. 2021-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210315893-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS S1PR1, S1PR3, S1PR2 MAPT 4876/4885L3MBTL1 2938/4885KDM4E 3835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.